In Arizona, individuals and patients who paid for clinical laboratory tests performed by Theranos, Inc., are finally getting refunds. These payments are a result of a settlement between the Arizona Attorney General and Theranos. News accounts indicate that, over the time in 2013 through 2016 that Theranos offered lab tests in Arizona through its relationship with
Tag: arup laboratoriesSkip to articles
ARUP Laboratories is a nonprofit national clinical and anatomic pathology reference laboratory, and an enterprise of the University of Utah and its Department of Pathology. Based in Salt Lake City, UT, it was founded in 1984. Currently its Chief Executive Officer is Edgar Braendle, MD, PhD.
With more than 3,000 employees, ARUP Lab offers in excess of 3,000 tests and test combinations, ranging from routine screening tests to highly esoteric molecular and genetic assays.
Rather than competing with its clients for physician office business, ARUP Lab supports clients’ existing test menus by offering highly complex and unique lab tests, with accompanying consultative support, to enhance their abilities to provide laboratory services.
ARUP offers diagnostic laboratory testing services to thousands of clients, including academic hospitals, children’s hospitals, multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics, in all 50 states. It is the reference lab of choice for more than 50 percent of the nation’s university medical centers, pediatric hospitals, and teaching hospitals.
ARUP’s clients include more than half of the nation’s university teaching hospitals and children’s hospitals, as well as regional hospital networks, multihospital groups, major commercial laboratories, group purchasing organizations, military and government facilities, and major clinics.
ARUP Lab is home to more than 60 individual labs specializing in all aspects of clinical and anatomic pathology. The test menu encompasses more than 3,000 tests, including highly specialized and esoteric tests. Comprehensive testing is offered in the areas of pathology, allergy and immunology, chemistry, cytogenetics, endocrinology, fetal risk assessment, genetics, hematology, hepatitis and HIV, infectious diseases, neurology, oncology, genetics, molecular oncology, anatomic pathology, pediatrics, and pain management, among others.
ARUP Lab performs 99 percent of all testing onsite in one central location, operating 24 hours per day, 7 days a week, and processing an average of 45,000–50,000 specimens of blood, body fluid, and tissue biopsies per day.
ARUP is a CLIA-certified diagnostic lab with more than 25 years of experience successfully supporting clinical trials. ARUP has more than 90 medical experts available for client consultation. These professionals hold faculty appointments at the University of Utah School of Medicine; many participate in care teams at the Huntsman Cancer Hospital and Primary Children’s Hospital.
CEO SUMMARY: In more than 40 presentations by 55 speakers, two big themes dominated the 11th annual Lab Quality Confab in New Orleans last week. One theme is the urgent need to cut clinical laboratory costs. The second theme is the need for both clinical labs and anatomic pathology groups to deliver more value to
FOR THE PAST SEVERAL YEARS, and particularly since Congress passed the Patient Access to Medicare Act in 2014, clinical labs have focused on controlling costs, as they should. After all, PAMA calls for steep cuts in what the federal Centers for Medicare and Medicaid Services will pay clinical labs beginning Jan. 1, 2018. (See TDRs,
Genetic testing for dogs is the goal of Embark Veterinary, of Boston, Mass. Founded in 2015, the company just raised $4.5 million from investors, including Anne Wojcicki, founder of 23andMe. Company executives say the genetic testing will help vets, pet owners, and breeders identify the disease risk of the dogs, as well as the animals’
PAML of Spokane, Washington, was the subject of an unusual public disclosure recently made by Laboratory Corporation of America. The lab company sent a statement to the Spokane Journal of Business stating its plans to make PAML “its primary lab site in the western U.S. for workplace and toxicology testing.” The statement was made to the
CEO SUMMARY: In Dallas, the relatively short-lived lab company known as Med Fusion has a new owner. After seven years, the lab partnership of Baylor Scott and White, US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories decided to sell their ownership stakes to Quest Diagnostics. The sale comes despite $100 million of capital and
CEO SUMMARY: Being accredited to this internationally recognized standard for quality and competence communicates to clients and prospective clients that one of the nation’s largest clinical labs is committed to the highest standards of quality. Clients already knew about that commitment but now have definitive proof, ARUP said. Also, lab administrators believed that gaining accreditation
Throughout the profession of laboratory medicine, concern is surfacing following publication of a proposed rule by the Department of Veterans Affairs (VA) that would expand the authority of Advanced Practice Registered Nurses (APRNs) to supervise and perform laboratory testing. This rule would expand APRNs’ authority, currently limited to ordering and interpreting lab tests. In an
CEO SUMMARY: To encourage more students to pursue medical technology (MT) and medical laboratory technician (MLT) degrees, ARUP Laboratories and Weber State University (WSU) are collaborating to promote the distance learning programs offered at WSU. Online students can work any shift and take courses anytime (day, night, or on weekends), thereby making education more accessible
It’s a lawsuit that Quest Diagnostics Incorporated can’t seem to make go away. Last week in California, a federal judge ruled Hunter Laboratories and Surgical Pathology Associates (SPA) can continue to pursue their antitrust lawsuit against Quest Diagnostics. Plaintiffs allege that Quest conspired to monopolize lab testing in California. Hunter Laboratories claimed it was harmed because Quest Diagnostics sold lab tests below cost. SPA claimed it was harmed because Quest had below-cost capitated con- tracts with certain payers.